Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Key facts

Sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd

Principal Investigator

Minghui Zhao, Postdoc

Peking University First Hospital

Intervention

BDB-001 injection(drug)

Enrollment

93 enrolled

Eligibility

18-75 years · All sexes

Timeline

2022 – 2025

Study locations (22)

• The Second hospital Of Anhui Medical University, Hefei, Anhui, China
• Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
• Peking University First Hospital, Beijing, Beijing Municipality, China
• Peking University International Hospital, Beijing, Beijing Municipality, China
• Guangxi Academy of Medical Sciences,The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region (gzar), China
• The Second hospital of Hebei Medical University, Shijiazhuang, Hebei, China
• The Third hospital of Hebei Medical University, Shijiazhuang, Hebei, China
• The First Affiliated Hospital of Henan University of science and Technology, Luoyang, Henan, China
• The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
• Tongji Hospital,Tongji Medical college of Hust, Wuhan, Hubei, China
• Xiangya Hospital Central South University (Nephrology Department), Changsha, Hunan, China
• Xiangya Hospital Central South University(Rheumatism Immunity Branch), Changsha, Hunan, China
• The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
• The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• Shengjing Hospital of China Medical University, Shengyang, Liaoning, China
• +7 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07556484
  Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
  Mayo Clinic
• RECRUITINGEARLY PHASE1NCT07507201
  Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
  The Children's Hospital of Zhejiang University School of Medicine
• RECRUITINGNCT07258524
  PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
  University of Edinburgh
• RECRUITINGPHASE1NCT07315087
  CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE2NCT07160608
  Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
  Alexion Pharmaceuticals, Inc.
• RECRUITINGPHASE3NCT07168161
  BDB-001 Phase III Trial in ANCA-Associated Vasculitis
  Staidson (Beijing) Biopharmaceuticals Co., Ltd
• RECRUITINGPHASE3NCT06983821
  Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
  Ottawa Hospital Research Institute
• RECRUITINGNCT07151521
  (68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
  Ruijin Hospital

See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →